Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACACIA-HCM: Aficamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
jRCT2031250066Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Primary endpoints: Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) and Change in peak oxygen uptake (pVO2). Started Jun 2025; status: active, not recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on jRCT2031250066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250066.